MX2017016991A - Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos. - Google Patents

Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.

Info

Publication number
MX2017016991A
MX2017016991A MX2017016991A MX2017016991A MX2017016991A MX 2017016991 A MX2017016991 A MX 2017016991A MX 2017016991 A MX2017016991 A MX 2017016991A MX 2017016991 A MX2017016991 A MX 2017016991A MX 2017016991 A MX2017016991 A MX 2017016991A
Authority
MX
Mexico
Prior art keywords
vitamin
preserving
health
formulation
coadjuvant
Prior art date
Application number
MX2017016991A
Other languages
English (en)
Inventor
SANTOS GARCÍA Arturo
Carlos Altamirano Vallejo Juan
Alonso CHAVÉZ GARCÍA José
Gonzalez De La Rosa Alejandro
Original Assignee
Centro De Retina Medica Y Quirurgica S C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Retina Medica Y Quirurgica S C filed Critical Centro De Retina Medica Y Quirurgica S C
Priority to MX2017016991A priority Critical patent/MX2017016991A/es
Priority to US16/954,401 priority patent/US11937625B2/en
Priority to ES18891919T priority patent/ES2962253T3/es
Priority to CA3102251A priority patent/CA3102251A1/en
Priority to PCT/MX2018/000154 priority patent/WO2019125127A1/es
Priority to EP18891919.5A priority patent/EP3730130B1/en
Priority to BR112020012073-1A priority patent/BR112020012073A2/pt
Priority to CN201880088073.7A priority patent/CN111712237A/zh
Priority to JP2020555757A priority patent/JP2021508502A/ja
Publication of MX2017016991A publication Critical patent/MX2017016991A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se presenta como invención una formulación nutracéutica para el consumo de extracto de arándano azul, aceite de pescado (Omega-3 y Omega-6), Lactoferrina humana recombinante, Vitamina A y Vitamina E por el ser humano vía oral. La invención se encuentra dentro del campo de la oftalmología y ha sido desarrollada como un coadyuvante para preservar la salud de la película lagrimal y de la superficie ocular. Esta formulación contiene un extracto de origen natural (Vaccinium myrtillus L) el cual tiene propiedades antioxidantes y antinflamatorias, además hace uso del Ácido eicosapentaenoico (EPA) omega 6 y del Ácido docosahexaenoico (DHA) omega 3 que se obtiene del aceite del pescado que, en conjunto con la lactoferrina, la vitamina A y vitamina E se logra una mejoría en la calidad de la lágrima al tener estos compuestos efectos antimicrobiales y antiinflamatorios. Esta formulación ha sido diseñada para coadyuvar en la salud de la película lagrimal. En el arte previamente descrito no existe una formulación para la administración oral de extracto de arándano azul en conjunto con lactoferrina, así como su combinación con vitamina A, vitamina E y aceite de pescado (ácido eicosapentanoico y ácido docohexaenoico) ni para su uso como adyuvante para la salud de la película lagrimal y/o de la superficie ocular.
MX2017016991A 2017-12-20 2017-12-20 Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos. MX2017016991A (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2017016991A MX2017016991A (es) 2017-12-20 2017-12-20 Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.
US16/954,401 US11937625B2 (en) 2017-12-20 2018-12-18 Oral administration formulation of blueberry extract as a coadjuvant for preserving the health of human precorneal film
ES18891919T ES2962253T3 (es) 2017-12-20 2018-12-18 Formulación para la administración oral de extracto del arándano azul como coadyuvante en la conservación de la salud de la película precorneal humana
CA3102251A CA3102251A1 (en) 2017-12-20 2018-12-18 Oral administration formulation of blueberry extract as a coadjuvant for preserving the health of human precorneal film
PCT/MX2018/000154 WO2019125127A1 (es) 2017-12-20 2018-12-18 Formulación para la administración oral de extracto del arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos
EP18891919.5A EP3730130B1 (en) 2017-12-20 2018-12-18 Oral administration formulation of blueberry extract as a coadjuvant for preserving the health of human precorneal film
BR112020012073-1A BR112020012073A2 (pt) 2017-12-20 2018-12-18 formulação de um suplemento alimentar
CN201880088073.7A CN111712237A (zh) 2017-12-20 2018-12-18 蓝莓提取物作为用于保持人体角膜前膜健康的辅助剂的口服施用制剂
JP2020555757A JP2021508502A (ja) 2017-12-20 2018-12-18 ヒト前角膜の健康維持のための補助剤としてのブルーベリー抽出物の経口投与配合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017016991A MX2017016991A (es) 2017-12-20 2017-12-20 Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.

Publications (1)

Publication Number Publication Date
MX2017016991A true MX2017016991A (es) 2019-06-21

Family

ID=66994110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016991A MX2017016991A (es) 2017-12-20 2017-12-20 Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.

Country Status (9)

Country Link
US (1) US11937625B2 (es)
EP (1) EP3730130B1 (es)
JP (1) JP2021508502A (es)
CN (1) CN111712237A (es)
BR (1) BR112020012073A2 (es)
CA (1) CA3102251A1 (es)
ES (1) ES2962253T3 (es)
MX (1) MX2017016991A (es)
WO (1) WO2019125127A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022016027A (es) * 2022-12-13 2024-06-14 Centro De Retina Medica Y Quirurgica S C Usos de una formulacion de administracion oral que contiene antocianinas y pterostilbenos del extracto de arandano azul, acidos grasos omega 3, lactoferrina, vitaminas a y e y excipientes con propiedades surfactantes para el tratamiento primario y/o como coadyuvante del sindrome de ojo seco en seres humanos.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702031A1 (de) * 1987-01-24 1988-08-04 Basf Ag Verfahren zur herstellung von mikrodispersen fischoelpraeparaten
FR2712823B1 (fr) * 1993-11-25 1996-02-23 Scherer Sa Rp Capsule molle de gélatine renfermant un mélange à forte teneur en eau.
US6608102B1 (en) * 1997-09-09 2003-08-19 Rutgers, The State University Of New Jersey Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with P-type fimbriae to surfaces
US5955102A (en) * 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
FR2856304B1 (fr) * 2003-06-20 2006-03-03 Natural Product Consulting Composition pour la prevention des infections du systeme urinaire
SE528337C2 (sv) * 2004-06-23 2006-10-24 Nestor Medical Ab Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
ITRM20060435A1 (it) * 2006-08-09 2008-02-10 Opocrin Spa Composizione a base di mirtillo rosso vaccinium mcrocarpon e lattoferrina per la prevenzione e il trattamento delle infezioni del tratto urinario
JP5106809B2 (ja) * 2006-08-15 2012-12-26 株式会社Ｎｒｌファーマ ラクトフェリンを含有する医薬組成物ならびに加工食品
US20110009313A1 (en) * 2008-03-14 2011-01-13 Nrl Pharma, Inc. Polyethylene glycolated lactoferrin complex and method of producing the same
JP2009221162A (ja) * 2008-03-17 2009-10-01 Yokohama Tlo Co Ltd ラクトフェリンを有効成分とするｕｃｐ発現促進剤
CN101731597B (zh) * 2008-11-05 2013-11-20 康魄商贸(上海)有限公司 蓝莓鱼油胶囊
JP2011051903A (ja) * 2009-08-31 2011-03-17 Nrl Pharma Inc ラクトフェリン徐放製剤の製造法
US20110280851A1 (en) * 2010-05-12 2011-11-17 Herzlinger Alexander S Compositions Comprising Cranberry Extract and Methods of Use Thereof
CN102379446B (zh) * 2011-11-03 2013-06-19 南昌大学 一种护目健眼饮料及其制备方法
JP6336373B2 (ja) * 2014-10-08 2018-06-06 株式会社えがお マリーゴールド抽出物を含有する加工食品
CN105029443A (zh) * 2015-07-06 2015-11-11 哈尔滨瑞康源生物科技有限公司 一种预防眼病、缓解视疲劳的营养食品及其制备方法

Also Published As

Publication number Publication date
US11937625B2 (en) 2024-03-26
JP2021508502A (ja) 2021-03-11
EP3730130C0 (en) 2023-08-16
CN111712237A (zh) 2020-09-25
WO2019125127A1 (es) 2019-06-27
CA3102251A1 (en) 2019-06-27
EP3730130A1 (en) 2020-10-28
EP3730130A4 (en) 2021-09-15
US20210076726A1 (en) 2021-03-18
BR112020012073A2 (pt) 2020-11-24
EP3730130B1 (en) 2023-08-16
ES2962253T3 (es) 2024-03-18

Similar Documents

Publication Publication Date Title
CL2017001614A1 (es) Proceso para aumentar la estabilidad de una composición que comprende ácidos grasos omega-3 poliinsaturados
MX2015008199A (es) Formulaciones de acido eicosapentaenoico (epa).
MX2011009740A (es) Coposiciones oftalmicas basadas en acidos grasos omega-3 y omega-6.
AR110060A1 (es) Composiciones nutricionales que proporcionan el manejo dietético de cólicos
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
CL2017001516A1 (es) Material de suplemento de piensos para uso en piensos para acuicultura.
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
ES2666322T3 (es) Composiciones farmacéuticas para el tratamiento de trastornos musculares
EA201791885A1 (ru) Смесь жирных кислот и её применение для лечения воспалительных патологий
WO2012049222A3 (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
CO2021014835A2 (es) Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso
BR112018001164A2 (pt) composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular
GEP20237543B (en) Pharmaceutical composition comprising omega fatty acids, and infusion preparation comprising the same
MX2021009825A (es) Suplemento alimenticio.
MX2017016991A (es) Formulación para la administración oral de extracto de arándano azul como auxiliar en la conservación de la salud de la película lagrimal en seres humanos.
RU2016129079A (ru) Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы
PE20211003A1 (es) Composiciones de acidos grasos poliinsaturados enriquecidos con dha
PH12020550961A1 (en) Stabilizing omega-3 fatty acids with bran
MX361765B (es) Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.
BR112018070194A2 (pt) composto e composição para uso
AR102545A1 (es) Suplementos nutricionales que contienen un componente peptídico y método de protección contra la obesidad
MX2017001880A (es) Formulación nutracéutica para la administración oral de pilocarpus microphyllus, lactoferrina y aceite de pescado en seres humanos.
AR070405A1 (es) Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual
CL2017002828A1 (es) Composición para tratamiento de estrés oxidativo y enfermedad cardiovascular